Cyclacel Pharmaceuticals Inc.
| NASDAQ: CYCC | Healthcare / Biotechnology / USA |
| 0.3502 | -0.0028 | -0.79% | Vol 18.41K | 1Y Perf -74.42% |
| Oct 3rd, 2023 15:59 DELAYED |
| BID | 0.3502 | ASK | 0.3600 | ||
| Open | 0.3531 | Previous Close | 0.3530 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 16.25 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 4.54K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★★ 55.46 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 5.80 | Earnings Rating | Sell | |
| Market Cap | 4.43M | Earnings Date | 8th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.25 | |
| Beta | 1.13 |
Today's Price Range 0.34310.3600 | 52W Range 0.28001.49 | 5 Year PE Ratio Range -0.8000-1.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.97% | ||
| 1 Month | -11.75% | ||
| 3 Months | -39.36% | ||
| 6 Months | -38.08% | ||
| 1 Year | -74.42% | ||
| 3 Years | -90.38% | ||
| 5 Years | -98.77% | ||
| 10 Years | -99.96% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -36.98 | |||
ROE last 12 Months | -62.58 | |||
ROA (5Y Avg) | -17.06 | |||
ROA last 12 Months | -55.75 | |||
ROC (5Y Avg) | -49.94 | |||
ROC last 12 Months | -56.85 | |||
Return on invested Capital Q | -18.26 | |||
Return on invested Capital Y | -13.59 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.36 | ||||
| 88.29 | ||||
| - | ||||
| -0.60 | ||||
| -1.90 | ||||
| 0.36 | ||||
| 2.12 | ||||
| -14 108 100.00 | ||||
| Forward PE | -0.11 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.40 | ||||
| 6.40 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -6 235.30 | ||||
| -6 220.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.54 | -0.44 | 18.52 |
| Q01 2023 | -0.68 | -0.47 | 30.88 |
| Q04 2022 | -0.53 | -0.60 | -13.21 |
| Q03 2022 | -0.55 | -0.42 | 23.64 |
| Q02 2022 | -0.67 | -0.46 | 31.34 |
| Q01 2022 | -0.67 | -0.42 | 37.31 |
| Q04 2021 | -0.71 | -0.54 | 23.94 |
| Q03 2021 | -0.70 | -0.54 | 22.86 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.45 | -7.14 | Negative |
| 12/2023 QR | -0.35 | 14.63 | Positive |
| 12/2023 FY | -1.65 | -15.38 | Negative |
| 12/2024 FY | -3.04 | -2.01 | Negative |
| Next Report Date | 8th Nov 2023 |
| Estimated EPS Next Report | -0.45 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 18.41K |
| Shares Outstanding | 12.64K |
| Shares Float | 10.99M |
| Trades Count | 53 |
| Dollar Volume | 6.54K |
| Avg. Volume | 59.10K |
| Avg. Weekly Volume | 25.44K |
| Avg. Monthly Volume | 60.53K |
| Avg. Quarterly Volume | 91.34K |
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 0.353 per share at the end of the most recent trading day (a -0.48% change compared to the prior day closing price) with a volume of 17.01K shares and market capitalization of 4.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.
The one-year performance of Cyclacel Pharmaceuticals Inc. stock is -74.42%, while year-to-date (YTD) performance is -47.08%. CYCC stock has a five-year performance of -98.77%. Its 52-week range is between 0.28 and 1.49, which gives CYCC stock a 52-week price range ratio of 5.80%
Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -55.75%, a ROC of -56.85% and a ROE of -62.58%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $16.25, which is +4 540.21% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclacel Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.50, ATR14 : 0.04, CCI20 : 84.91, Chaikin Money Flow : -0.31, MACD : -0.02, Money Flow Index : 72.58, ROC : 22.65, RSI : 46.96, STOCH (14,3) : 91.25, STOCH RSI : 0.96, UO : 57.93, Williams %R : -8.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were:
Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
CEO: Spiro Rombotis
Telephone: +1 908 517-7330
Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US
Number of employees: 12
